Today the EU licensed siponimod for the treatment of active secondary progressive MS. It has been a very long and winding road to get here.
Siponimod is not an eagle, phoenix or maven, but rather a hopebird which symbolises the importance of “an optimistic approach to what lies ahead”. Less than a decade ago we were telling our patients with a progressive course that they were beyond hope, that has now changed.
Being able to offer treatment to people with SPMS will be a challenge to the NHS, because of the way our services are configured, but it is doable. If there is a will to make it happen it will happen.
The next task is to challenge the term ‘active’ SPMS. What does it really mean? How can you tell someone with worsening SPMS they don’t have active SPMS. I think it is time to challenge the old dogmas that thave crept into our field. I also hope siponimod will be a segway into a new era of combination therapy.
CoI: multiple; in particular, I sit on the Siponimod SPMS trial steering committee